68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases.
Souvatzoglou
M
M
Department of Nuclear Medicine, Klinikum-rechts-der-Isar, Muenchen, Germany.
Maurer
T
T
Treiber
U
U
Weirich
G
G
Krause
B J
BJ
Essler
M
M
D000813:Anilides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002454:Cell Differentiation; D002945:Cisplatin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D015282:Octreotide / Q000031:analogs & derivatives*; D049268:Positron-Emission Tomography; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology*; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000379:methods; D014105:Tosyl Compounds / Q000627:therapeutic use
D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D019275:Radiopharmaceuticals; D014105:Tosyl Compounds; D005047:Etoposide; C053541:bicalutamide; D017430:Prostate-Specific Antigen; D002945:Cisplatin; D015282:Octreotide; C106246:Edotreotide